, Volume 30, Issue 9, pp 303-308
Date: 15 Jul 2014

Dimethyl fumarate: a guide to its use in relapsing-remitting multiple sclerosis

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Oral dimethyl fumarate (Tecfidera®) is a useful addition to the therapeutic options available to treat relapsing-remitting MS (RRMS). In placebo-controlled trials in patients with RMSS, dimethyl fumarate 240 mg twice daily reduced the annualized relapse rate, the proportion of patients with MS relapse at 2 years, and magnetic resonance imaging-assessed disease activity. Dimethyl fumarate was generally well tolerated, with the most commonly occurring adverse events including flushing and gastrointestinal events. According to interim results of a long-term extension study, dimethyl fumarate provides continued efficacy for up to 4 years of treatment, with no new tolerability concerns.